Pharmaceutical Investing Apellis Pharmaceuticals Provides Update on Phase 1b Open Label Study of APL-2 in PNH Patients Not Previously Treated with Eculizumab
Fortune Minerals Reports Successful NICO Project Bismuth Test Work Results for the Planned Alberta Refinery